Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | RNASEL | Q05823 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1895177 | 1.00 | ESR1 (0.46) | ESR1TSHRRNASELLMNACYP1A2 | |
| SCHEMBL1892130 | 0.90 | SLC2A1 (0.47) | ESR1TSHRRNASELLMNACYP1A2 | |
| SCHEMBL1892127 | 0.90 | SLC2A1 (0.47) | ESR1TSHRRNASELLMNACYP1A2 | |
| SCHEMBL1895305 | 0.81 | SLC2A1 (0.44) | ESR1TSHRRNASELLMNACYP1A2 | |
| SCHEMBL1895303 | 0.81 | SLC2A1 (0.44) | ESR1TSHRRNASELLMNACYP1A2 | |
| SCHEMBL1896472 | 0.80 | SLC2A1 (0.48) | ESR1TSHRRNASELLMNACYP1A2 | |
| SCHEMBL1896469 | 0.80 | SLC2A1 (0.48) | ESR1TSHRRNASELLMNACYP1A2 | |
| SCHEMBL1893723 | 0.75 | GCG (0.37) | CYP2C19CYP2C9 | |
| SCHEMBL1893726 | 0.75 | GCG (0.44) | CYP2C19CYP2C9 | |
| SCHEMBL1897086 | 0.75 | GCG (0.44) | CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935713-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090105310-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds and Methods of Use | MERCK SHARP & DOHME LLC | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105310-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds and Methods of Use | GCGR, GLP1R, GPR119 | ESR1 559/4885TSHR 88/4885RNASEL 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.